Unknown

Dataset Information

0

Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.


ABSTRACT: There is no consensus on the most effective strategy (mammography or magnetic resonance imaging (MRI)) for screening women with BRCA1 or BRCA2 mutations. The effectiveness and cost-effectiveness of the Dutch, UK and US screening strategies, which involve mammography and MRI at different ages and intervals were evaluated in high-risk women with BRCA1 or BRCA2 mutations.Into a validated simulation screening model, outcomes and cost parameters were integrated from published and cancer registry data. Main outcomes were life-years gained and incremental cost-effectiveness ratios. The simulation was situated in the Netherlands as well as in the United Kingdom, comparing the Dutch, UK and US strategies with the population screening as a reference. A discount rate of 3% was applied to both costs and health benefits.In terms of life-years gained, the strategies from least to most cost-effective were the UK, Dutch and US screening strategy, respectively. However, the differences were small. Applying the US strategy in the Netherlands, the costs were €43 800 and 68 800 for an additional life-year gained for BRCA1 and BRCA2, respectively. At a threshold of €20 000 per life-year gained, implementing the US strategy in the Netherlands has a very low probability of being cost-effective. Stepping back to the less-effective UK strategy would save relatively little in costs and results in life-years lost. When implementing the screening strategies in the United Kingdom, the Dutch, as well as the US screening strategy have a high probability of being cost-effective.From a cost-effectiveness perspective, the Dutch screening strategy is preferred for screening high-risk women in the Netherlands as well as in the United Kingdom.

SUBMITTER: de Bock GH 

PROVIDER: S-EPMC3668482 | biostudies-other | 2013 Apr

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC3446401 | biostudies-literature
| S-EPMC4318608 | biostudies-literature
| S-EPMC5927761 | biostudies-literature
| S-EPMC6378691 | biostudies-other
| S-EPMC7109296 | biostudies-literature
| S-EPMC5406158 | biostudies-literature
| S-EPMC2747571 | biostudies-other
| S-EPMC2423214 | biostudies-literature
| S-EPMC7527375 | biostudies-literature
| S-EPMC8221716 | biostudies-literature